Accessibility Menu
Exagen logo

Exagen

(NASDAQ) XGN

Current Price$4.69
Market Cap$106.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-76%
5 Year-67%
1 Year-39%
1 Month+3%
Exagen last closing stock price
MetricPriceDate
Last closeUSD 4.392026-07-17
Exagen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.35%USD 4.452026-07-10
1 month+3.29%USD 4.252026-06-17
3 month+42.53%USD 3.082026-04-17
Year to date-27.8%USD 6.082025-12-31
1 year-38.86%USD 7.182025-07-17
3 year+62.89%USD 2.702023-07-18
5 year-66.92%USD 13.272021-07-16
Since inception-76.37%USD 18.582019-09-19

Exagen Financials at a Glance

Market Cap

$106.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$68.38M

Net Income (TTM)

-$20.17M

EPS (TTM)

-$0.88

P/E Ratio

-4.97

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$4.69

Volume

11,773

Open

$4.47

Previous Close

$4.39

Daily Range

$4.47 - $4.92

52-Week Range

$2.59 - $12.23

Estimated Earnings Date

Aug 4, 2026

XGN News

Foolcom-Featured.png

Exagen Q2 Revenue Jumps 14 Percent

Motley Fool Markets TeamJul 29, 2025

XGN: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Exagen

Exagen Inc. operates in the healthcare diagnostics sector, focusing on innovative test solutions for autoimmune diseases. The company's primary objective is to enhance diagnostic clarity and improve patient management. Exagen's key offerings include the AVISE brand of testing products, which are designed to aid in the diagnosis, prognosis, and monitoring of complex autoimmune diseases, such as lupus and rheumatoid arthritis. The company leverages advanced technologies, such as its proprietary CB-CAPs technology, to provide more accurate and comprehensive results than traditional methods.

Products and Services

AVISE CTD: A comprehensive test for diagnosing connective tissue diseases, including systemic lupus erythematosus and rheumatoid arthritis.

AVISE Lupus: A specific test aiding in the diagnosis of systemic lupus erythematosus.

AVISE MTX: A test designed to monitor methotrexate therapy in rheumatoid arthritis patients.

AVISE SLE Monitor: A monitoring tool for lupus patients assessing disease activity through biomarkers.

AVISE Anti-CarP: A prognostic test aimed at identifying severe cases of rheumatoid arthritis.

What Makes Exagen Inc. Special

Exagen Inc. stands out with its proprietary CB-CAPs technology, which enhances diagnostic precision for autoimmune diseases. This technology provides more specific and sensitive test results, supporting more accurate and timely diagnoses compared to conventional methods. Additionally, with a dedicated sales force and strategic collaborations, Exagen is well-positioned to expand its market presence and capture a significant share of the growing autoimmune diagnostics market.

Five Things You Need to Know

Exagen's AVISE CTD test has aided in the diagnosis of numerous autoimmune and related diseases since its launch in 2012.

The proprietary CB-CAPs technology is central to Exagen's competitive advantage, enabling more accurate diagnostics.

Exagen delivered approximately 137,650 AVISE CTD tests in 2023, marking a growth in their testing volume.

The company maintains a proprietary database of de-identified patient test results, providing insights for further research and development.

Exagen's strategic collaborations with institutions enhance its product development and market entry efforts.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

216

CEO

John Aballi, MBA

Website

www.exagen.com

Headquarters

Vista, CA 92081, US

XGN Financials

Key Financial Metrics (TTM)

Gross Margin

58.32%

Operating Margin

-20.65%

Net Income Margin

-29.49%

Return on Equity

-113.53%

Return on Capital

-32.60%

Return on Assets

-38.81%

Earnings Yield

-20.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$106.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.16M

Volume

11.77K

Avg. Volume

393.22K

Financials (TTM)

Gross Profit

$39.88M

Operating Income

-$14.12M

EBITDA

-$12.91M

Operating Cash Flow

-$13.37M

Capital Expenditure

-$756.00K

Free Cash Flow

-$14.13M

Cash & ST Invst.

$21.51M

Total Debt

$25.35M

Exagen Performance Analysis

Exagen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 45,563,000-5.7%
20232023-12-31USD 52,548,00015.3%
20242024-12-31USD 55,641,0005.9%
20252025-12-31USD 66,575,00019.7%
Exagen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.0%
Q32025-09-300.2%
Q42025-12-31-3.6%
Q12026-03-314.1%
Exagen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7765.0%
20232023-12-31USD -1.34-51.7%
20242024-12-31USD -0.83-38.0%
20252025-12-31USD -0.9311.4%
Exagen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-5.0%
Q32025-09-30-47.6%
Q42025-12-3132.3%
Q12026-03-3119.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$17.31M

+11.7%

Gross Profit

$10.21M

+11.9%

Gross Margin

58.97%

N/A

Market Cap

$106.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$491.03K

N/A

Employees

216

N/A

Net Income

-$3.97M

-5.7%

EBITDA

-$2.07M

+25.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$21.51M

+92.2%

Total Debt

$25.35M

+8.2%

Accounts Receivable

$15.77M

+7.1%

Inventory

$0.00

N/A

Long Term Debt

$22.40M

+13.3%

Short Term Debt

$2.95M

-19.4%

Return on Assets

-38.81%

N/A

Return on Invested Capital

-35.84%

N/A

Free Cash Flow

-$10.65M

+1.3%

Operating Cash Flow

-$10.42M

+2.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LFCRLifecore Biomedical, Inc.
$4.70+0.34%
MDXHMDxHealth S.A.
$0.42-1.80%
SMTISanara MedTech Inc.
$25.09+0.36%
SGHTSight Sciences, Inc.
$5.07+0.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$98.61+0.04%
HLHecla Mining
$14.38+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.94-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$68.98+0.02%

Questions About XGN

What is the current price of Exagen?

Exagen is trading at $4.69 per share.

What is the 52-week range for Exagen?

Over the past 52 weeks, Exagen has traded between $2.59 and $12.23.

How much debt does Exagen have?

As of the most recent reporting period, Exagen reported total debt of $27.15M.

How much cash does Exagen have on hand?

Exagen reported $21.51M in cash and cash equivalents in its most recent financial results.

What is Exagen’s dividend yield?

Exagen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services